Studying patient position and BCG hold time in bladder cancer treatment
Studies whether body position relates to how long BCG stays in the bladder.
Key facts
- Who runs it
- Ohio State University Comprehensive Cancer Center
- Where
- Columbus, United StatesSee the site
- Trial code
- Registry title
- Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 40 people, planned
- Started
- 26 Feb 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Treatments tested
- Accelerometry
- BCG Solution
- Electronic Health Record Review
- Patient Discharge
- Survey Administration
- Record updated
- 16 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with intermediate or high risk non-muscle invasive bladder cancer who are about to start BCG treatment in the bladder. It studies how body position and the time BCG stays in the bladder are related.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Intermediate or high risk non-muscle invasive bladder cancer (NMIBC), choosing intravesical induction BCG
- Earlier treatment
- Has not started induction therapy. Cannot have had intravesical BCG within the past 1 year.
Main reasons for not taking part
- Had intravesical BCG within the past 1 year
- Known inability to retain BCG
- History of urinary incontinence with a score of 3 or more on the Overactive Bladder Survey (urgency, urgency incontinence or incontinence questions)
- Refuses to wear a fitness tracker during the 24-hour baseline, during treatment and/or for 2 hours after treatment
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patient with intermediate or high risk NMIBC opting for intravesical induction BCG
- Has not initiated induction therapy
- Able to remain in supine position for two hours. (Head may be raised on up to two pillows)
- Able to remain in a sitting position for two hours
- Willingness to utilize a wearable fitness tracker for at least five days during the study
- Able to perform a remote video or telephone encounter
- Able to provide informed consent
Who cannot take part
- History of urinary incontinence with a score of 3 or more on the Overactive Bladder Survey (OAB) urgency, urgency incontinence, or incontinence questions
- Receipt of intravesical BCG within the past 1 year
- Known inability to retain BCG
- Refusal to wear a fitness tracker during a 24-hour baseline, during treatment, and/or for 2 hours post treatment
Where in United States
- Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Cheryl T. Lee, MDTaking people
About the trial
What the trial wants to find out
This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time) to improve the treatment of non-muscle invasive bladder cancer. For the past 40 years, intravesical BCG has been used for the treatment of non-muscle invasive bladder cancer. An important factor for BCG treatment is the dwell time, which is the period of time a patient can hold the BCG medication in the bladder after it has been given. Normally, patients are instructed during intravesical BCG treatment to avoid emptying the bladder for 2 hours after the BCG is given. However, this may be difficult for some patients who may have limited bladder capacity, restricted movement, or severe urinary symptoms. There have been studies outlining the relationship with increased dwell time and how well the treatment works, but studies on the potential impact of patient positioning or activity on the patient's ability to retain the drug are limited. Researchers hope by studying whether there is a relationship between patient positioning during intravesical BCG treatment and dwell time, they may be able to improve how BCG treatment for non-muscle invasive bladder cancer is given, especially for patients with limited bladder capacity, restricted movement, or severe urinary symptoms.
The group in the trial
- Treatment (BCG no restrictions, BCG lying down, BCG sitting)Treatment being tested
Patients receive SOC BCG therapy QW and post-treatment activity guidance for the first three weekly BCG installations in the absence of disease progression or unacceptable toxicity. FIRST TREATMENT: Patients receive SOC BCG intravesically and instructions to avoid urination for two hours with no activity restrictions and immediate clinic discharge. SECOND TREATMENT: Patients receive SOC BCG intravesically and remain in a lying down position for as long as able to hold treatment in for up to 2 hours. THIRD TREATMENT: Patients receive SOC BCG intravesically and remain in a sitting position for as long as able to hold treatment in for up to 2 hours. Additionally, patients receive and wear a Fitbit activity tracker throughout the study.
Treatment: Accelerometry, BCG Solution, Electronic Health Record Review, Patient Discharge, and Survey Administration
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Assessment of Patient Position and Intravesical BCG Dwell Time
- Plain-language title
- Studying patient position and BCG hold time in bladder cancer treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 March 2026